1-N-甲磺酰基-4-哌啶酮 | 218780-53-1

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-N-甲磺酰基-4-哌啶酮
• 中文别名: N-甲磺酰基-4-哌啶酮；1-甲磺酰基-4-哌啶酮；1-(甲基磺酰)-4-哌啶酮；1-(甲磺酰基)哌啶-4-酮；1-(甲基磺酰基)-4-哌啶酮
• 英文名称: 1-(methylsulfonyl)piperidin-4-one
• 英文别名: 1-methanesulfonyl-piperidin-4-one；1-N-methanesulfonyl-4-piperidone；1-N-(Methylsulfonyl)-4-piperidinone；1-methylsulfonylpiperidin-4-one
• CAS: 218780-53-1
• 化学式: C₆H₁₁NO₃S
• mdl: MFCD08061935
• 分子量: 177.224
• InChiKey: RTBFRGCFXZNCOE-UHFFFAOYSA-N

物化性质

• 熔点：
  102-103 °C
• 沸点：
  320.4±52.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2935009090
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-N-(Methylsulfonyl)-4-piperidinone
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-N-(Methylsulfonyl)-4-piperidinone
CAS number: 218780-53-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H11NO3S
Molecular weight: 177.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-N-甲磺酰基-4-哌啶酮 在 镍 吡啶 、 盐酸 、 sodium hypophosphite 、 水 、 caesium carbonate 、 对甲苯磺酸 、 溶剂黄146 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 、 苯 为溶剂， 反应 220.25h， 生成 2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-benzaldehyde
  参考文献：
  名称：

  WO2008/100620

  摘要：

  公开号：
• 作为产物：
  描述：

  8-(甲基磺酰基)-1,4-二氧杂-8-氮杂螺[4.5]癸烷 在 草酸 、 溶剂黄146 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以77%的产率得到1-N-甲磺酰基-4-哌啶酮
  参考文献：
  名称：

  BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE DERIVATIVES USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE

  摘要：

  公开号：

  EP0993460B1

文献信息

• BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same
  申请人：Ackler Scott L.

  公开号：US20160158377A1

  公开（公告）日：2016-06-09

  Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.

  小分子Bcl-xL抑制剂和包括小分子Bcl-xL抑制剂的抗体药物结合物（ADCs）在此披露。披露的Bcl-xL抑制剂和ADCs可用于抑制抗凋亡Bcl-xL蛋白，作为治疗涉及失调凋亡途径的疾病的治疗方法之一。
• Reverse hydroxamate inhibitors of matrix metalloproteinases
  申请人：Abbott Laboratories

  公开号：US06294573B1

  公开（公告）日：2001-09-25

  Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

  具有以下化学式的化合物是基质金属蛋白酶抑制剂。还公开了抑制基质金属蛋白酶的组合物和方法，用于在哺乳动物中抑制基质金属蛋白酶。
• An Efficient Synthesis of Substituted Pyrazoles from One-Pot Reaction of Ketones, Aldehydes, and Hydrazine Monohydrochloride
  作者：Vit Lellek、Cheng-yi Chen、Wanggui Yang、Jie Liu、Xuebao Ji、Roger Faessler

  DOI：10.1055/s-0036-1591941

  日期：2018.5

  hydrazine monohydrochloride readily formed pyrazoline intermediates under mild conditions. Oxidation of pyrazolines, in situ, employing bromine afforded a wide variety of pyrazoles. The methodology offers a fast, and often chromatography-free protocol for the synthesis of 3,4,5-substituted pyrazoles in good to excellent yields. Alternatively, a more benign oxidation protocol affords 3,5-disubstituted or

  开发了一种高效、单锅且无金属的制备多克规模的 3,5-二取代和 3,4,5-三取代吡唑的方法。在温和条件下，酮、醛和肼单盐酸盐的一锅缩合容易形成吡唑啉中间体。使用溴原位氧化吡唑啉得到多种吡唑。该方法为合成 3,4,5-取代吡唑的 3,4,5-取代吡唑类化合物提供了一种快速且通常无需色谱的方案，收率非常好。或者，通过简单地在 DMSO 中在氧气下加热吡唑啉，更温和的氧化方案提供 3,5-二取代或 3,4,5-三取代的吡唑。
• Insertion of an Aspartic Acid Moiety into Cyclic Pseudopeptides:  Synthesis and Biological Characterization of Potent Antagonists for the Human Tachykinin NK-2 Receptor
  作者：Valentina Fedi、Maria Altamura、Giuseppe Balacco、Franca Canfarini、Marco Criscuoli、Danilo Giannotti、Alessandro Giolitti、Sandro Giuliani、Antonio Guidi、Nicholas J. S. Harmat、Rossano Nannicini、Franco Pasqui、Riccardo Patacchini、Enzo Perrotta、Manuela Tramontana、Antonio Triolo、Carlo Alberto Maggi

  DOI：10.1021/jm040832y

  日期：2004.12.1

  A new series of monocyclic pseudopeptide tachykinin NK-2 receptor antagonists has been derived from the lead compound MEN11558. A synthesis for these molecules sharing the same intermediate was designed and performed. The replacement of the succinic moiety with an aspartic acid and the functionalization of its amino group with a wide variety of substituents led to very potent and selective NK-2 antagonists

  从先导化合物MEN11558衍生出一系列新的单环假肽速激肽NK-2受体拮抗剂。设计和执行了这些分子共享相同中间体的合成。用天冬氨酸替换琥珀酸部分，并用多种取代基对其氨基进行官能化，产生了非常有效和选择性的NK-2拮抗剂。最好的结果是通过在R的12位氨基酸上插入一个短间隔基与饱和氮杂环（​​吗啉，哌啶或哌嗪）相连而获得的。该研究产生了化合物54和57，它们在支气管收缩动物模型中以非常低的剂量具有很高的体内效力，并且作用时间长。
• [EN] SUBSTITUTED HETERO-AZEPINONES<br/>[FR] HÉTÉRO-AZÉPINONES SUBSTITUÉES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014023708A1

  公开（公告）日：2014-02-13

  There are provided compounds of the formula (1) wherein W, X, Y, Z, R1, R2, R3, R4, R5 and R6 are described herein. These compounds are useful for the treatment of proliferative diseases, including cancer.

  提供了符合式（1）的化合物，其中W、X、Y、Z、R1、R2、R3、R4、R5和R6如本文所述。这些化合物对于治疗增殖性疾病，包括癌症，是有用的。